Evaluation of LL 37 lipoprotein as innate immunity marker among Sudanese patients cutaneous leishmania

Ayat  H. Bakr; E.A.  Abugroun; AbdElkarim  A. Abdrabo; Omeyma  A. Mohamed; M.A.  Mokhtar; GadAllah  Modawe

doi:10.52981/sjms.v14i3.1488

Ayat H. Bakr Department of Microbiology, University of Science and Technology, Khartoum, Sudan
E.A. Abugroun University of Science and Technology, Khartoum, Sudan
AbdElkarim A. Abdrabo Department of Clinical Chemistry, Faculty of Medical Laboratories Science, Al-Neelain University, Khartoum, Sudan
Omeyma A. Mohamed Department of Clinical Chemistry, Faculty of Medical Laboratories Science, Sudan International University, Khartoum, Sudan
M.A. Mokhtar The Institute of Endemic Diseases, University of Khartoum, Sudan
GadAllah Modawe Omdurman Islamic university, Faculty of Medicine, Department of Biochemistry, Omdurman, Sudan

DOI: https://doi.org/10.52981/sjms.v14i3.1488

الملخص

Background: The leishmaniasis is a group of diseases with a broad range of clinical manifestations caused by several species of parasites belonging to the genus Leishmania. LL-37/hCAP18, the only cathelicidin in human, is expressed as an 18-kDa preproprotein. The most prominent function of cathelicidin is their ability to inhibit propagation of a diverse range of microorganisms, which occurs at a micromolar range.

Objective: The study was aimed to evaluate the LL37 plasma level in Leishmania Sudanese patients.

Methods: In a case-control study, 300 subjects were enrolled (200 as case and 100 controls); 5 ml venous blood was collected in EDTA container, then plasma was obtained and stored frozen at –80°C. LL 37 was estimated using competitive ELISA. The data were analyzed using SPSS version 21.

Results: The results revealed that 115 (57%) of Leishimania patients were male and 85 (43%) were female. Plasma LL 37 level was significantly increased in Leishmania patients (1.30 ± 0.71) compared to the control (0.21 ± 0.20) with (p-value 0.000).

Conclusion: Leishmania patients had higher levels of plasma LL37, suggesting effective antimicrobial immunity process enhancing healing of cutaneous leishmaniasis.

المراجع

[1] Osman, O. F., Kager, P. A., and Oskam, L. (2000). Leishmaniasis in Sudan: a literature review with emphasis on clinical aspects. Tropical Medicine and International Health, vol. 5, no. 8, pp. 553–562.
[2] Abdalla, R. E., Ali, M., Wasfi, A. I., et al. (1973). Cutaneous leishmaniasis in Sudan. Transactions of the Royal Society of Tropical Medicine and Hygiene, vol. 67, no. 4,pp. 549–559.
[3] El-Safi, S. H., Peters, W., El-Toam, B., et al. (1991). Studies on the leishmaniases in Sudan. 2. Clinical and parasitological studies on cutaneous leishmaniasis. Trans- actions of the Royal Society of Tropical Medicine and Hygiene, vol. 85, no. 4, pp. 457–464.
[4] Abdalla, R. E. and Sherif, H. (1978). Epidemic of cutaneous leishmaniasis in northern Sudan. Annals of Tropical Medicine & Parasitology, vol. 72, no. 4, pp. 349–352.
[5] Abdalla, R. E., El Hadi, A., Ahmed, M. A., et al. (1975). Sudan mucosal leishmaniasis. Transactions of the Royal Society of Tropical Medicine and Hygiene, vol. 69, no. 5–6, pp. 443–449.
[6] Wu. W. K., Wang, G., Coffelt, S. B., et al. (2010). Emerging roles of the host defense peptide LL-37 in human cancer and its potential therapeutic applications. International Journal of Cancer, vol. 127, no. 8, pp. 1741–1747.
[7] Gallo, R. L. and Nizet, V. (2003). Endogenous production of antimicrobial peptides in innate immunity and human disease. Current Allergy and Asthma Reports, vol. 3, pp. 402–409.
[8] Huang, H. J., Ross, C. R., and Blecha, F. (1997). Chemoattractant properties of PR-39, a neutrophil antibacterial peptide. Journal of Leukocyte Biology, vol. 61, pp. 624–629.
[9] De, Y., Chen, Q., Schmidt, A. P., et al. (2000). LL-37, the neutrophil granule- and epithelial cell-derived cathelicidin, utilizes formyl peptide receptor-like 1 (FPRL1) as a receptor to chemoattract human peripheral blood neutrophils, monocytes, and T cells. Journal of Experimental Medicine, vol. 192, pp. 1069–1074.
[10] Heilborn, J. D., Nilsson, M. F., Kratz, G., et al. (2003). The cathelicidin anti-microbial peptide LL-37 is involved in reepithelialization of human skin wounds and is lacking in chronic ulcer epithelium. Journal of Investigative Dermatology, vol. 120, pp. 379– 389.
[11] Yang, Y. H., Wu, W. K., Tai, E. K., et al. (2006). The cationic host defense peptide rCRAMP promotes gastric ulcer healing in rats. Journal of Pharmacology and Experimental Therapeutics, vol. 318, pp. 547–554.
[12] Zasloff, M. (2002). Antimicrobial peptides of multicellular organisms. Nature, vol. 415, no. 6870, p. 389.
[13] Vandamme, D., Landuyt, B., Luyten, W., et al. (2012). A comprehensive summary of LL-37, the factotum human cathelicidin peptide. Cellular Immunology, vol. 280, no. 1, pp. 22–35.
[14] Bucki, R., Leszczyńska, K., Namiot, A., et al. (2010). Cathelicidin LL-37: a multitask antimicrobial peptide. Archivum Immunologiae et Therapiae Experimentalis, vol. 58, no. 1, pp. 15–25.
[15] Kulkarni, M. M., Barbi, J., McMaster, W. R., et al. (2011). Mammalian antimicrobial peptide influences control of cutaneous Leishmania infection. Cell Microbiology, vol. 13, pp. 913–923.